29 October 2026
Eli Lilly raises its sales forecast as its weight-loss shots keep beating estimates
Lilly's third-quarter revenue hit $24.4 billion, about $1.8 billion above forecasts, and it now expects up to $92 billion of 2026 sales. Its new obesity pill fell short.
Eli Lilly's diabetes and weight-loss shots had another enormous quarter. On Thursday the drugmaker reported third-quarter results well above Wall Street's forecasts and raised its full-year sales outlook, and its shares rose about 7%. The one soft spot was its new obesity pill.
What happened
Revenue came in at $24.40 billion, against the $22.61 billion analysts expected in an LSEG survey. Adjusted earnings, which exclude some one-time items, were $7.48 a share versus $6.26 expected. Net income was $6.45 billion, up from $5.58 billion a year earlier.
- Mounjaro, the diabetes shot, grew 65% to $10.72 billion. Sales outside the US jumped 93%.
- Zepbound, the same medicine sold for weight loss, grew 49% to $5.35 billion, almost all of it in the US.
- Foundayo, the obesity pill launched in April, brought in $184 million, below the roughly $229 million analysts expected.
Lilly now expects 2026 revenue of $91 billion to $92 billion, up from $85 billion to $87 billion. Oddly, its adjusted profit forecast edged down, to $35 to $36 a share. That is because charges tied to deals struck in the quarter, worth $4.57 a share, more than cancel out a $4.07 raise from the underlying business.
Why it matters
The growth is coming from volume, not price. US revenue rose 34% to $15.1 billion as the number of prescriptions and units sold climbed 41%, while the price Lilly actually collected fell 7%. Prices have come down since a drug pricing deal with the Trump administration last year, and Medicare began covering GLP-1 drugs (the class of medicines that includes Mounjaro and Zepbound) for weight loss in July under a temporary pilot. Selling far more at a bit less turns out to be a fine way to make more money.
Lilly also keeps widening its lead over Danish rival Novo Nordisk. Its slides put Lilly's share of the US obesity and diabetes drug market at 63% in the quarter, against 36.6% for Novo. Chief executive Dave Ricks told CNBC he thinks only 3% to 10% of eligible US patients get obesity care today.
All of this is priced into a very large company. Lilly was worth about $1.15 trillion at Tuesday's close, and its share price was nearly 43 times its yearly profit, according to Noorult data.
What to watch
- A US approval decision for Foundayo in type 2 diabetes, which Lilly expects in the fourth quarter.
- Whether Foundayo can gain ground on Novo's rival obesity pill, which launched in January.
- Lilly's deal-making, including its agreement to buy Merida Biosciences, which works on autoimmune and allergic diseases.
Lilly's full financials are on its Noorult company page.
The companies in this story
Based on reporting by CNBC: Eli Lilly (LLY) earnings Q3 2026. Facts, not advice.
More news
- Anthropic's IPO, in numbers: 825 million shares at $70 to $78, and a $1.4 trillion price tag
- Trump says the Nvidia scandal didn't endanger US security, and stands by Lutnick
- Nvidia's first earnings without Huang: what Kress will be asked on Tuesday
- Buffett gives away $5.5 billion of Berkshire stock in his Thanksgiving letter
- Banks are using AI to trim back offices. Proof that it adds revenue is harder to find
- IMF chief says the world economy leans too hard on AI as circular deals top $1 trillion